Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) has shared an update.
Race Oncology has achieved significant milestones with its lead oncology asset, RC220, including the initiation of a Phase 1a/b trial in combination with doxorubicin for advanced solid tumors. The company has filed patents for the single active isomer of bisantrene, potentially extending exclusivity to 2045, and is advancing a lung cancer trial to address drug resistance. These developments strengthen Race Oncology’s clinical capabilities and intellectual property portfolio, enhancing its commercial value and positioning in the oncology market.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company focused on cancer care, with its lead asset, RCDS1 (E,E-bisantrene), targeting cancer growth through G4-DNA & RNA binding. The company is advancing its proprietary formulation, RC220, across multiple oncology indications, including acute myeloid leukemia and non-small cell lung cancer, and is exploring partnerships to enhance global patient access.
Average Trading Volume: 546,429
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$514.5M
Learn more about RAC stock on TipRanks’ Stock Analysis page.